CommercialCoverageMedium impact
08.01.75e, Margetuximab-cmkb (Margenza)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Commercial insurance policies have been updated regarding Margetuximab-cmkb (Margenza), a targeted therapy medication used in oncology. This appears to be a pharmacy policy update that may affect coverage, prior authorization, or billing requirements for this specialized cancer treatment.
Action Required
By October 1, 2025: Billing and pharmacy teams should review the full policy details at the provided URL to understand specific changes to Margetuximab-cmkb (Margenza) coverage requirements. Oncology practices should verify current prior authorization requirements and update billing procedures accordingly. Contact the payer directly if clarification is needed on coverage criteria.